Additionally, it highlights the necessity for clinicians to maintain a high index of suspicion for EDKA in patients on SGLT2 inhibitors presenting with unexplained high anion gap metabolic acidosis, even when blood glucose levels are not significantly elevated. Here, SLC5A2 is linked to metabolic process.